Mazdutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A dual GLP-1 and glucagon receptor agonist for weight loss and blood sugar control. Human evidence for weight loss and glucose control is strong, though long-term safety data are limited and liver benefit evidence is weak. Gastrointestinal side effects are common, heart rate can rise, and hypoglycemia is a risk at higher doses, while thyroid tumor risk remains theoretical. It is not an approved drug in the US; supply is unregulated research-grade product.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Mazdutide (IBI362) is a once-weekly injectable that activates two gut hormone receptors simultaneously -- GLP-1 and glucagon -- to achieve greater weight loss than GLP-1-only drugs like semaglutide. It is a lab-made version of oxyntomodulin, a natural hormone released by your gut after eating. Developed by Innovent Biologics and Eli Lilly, mazdutide became the world's first dual GLP-1/glucagon receptor agonist to receive regulatory approval when China's NMPA approved it for chronic weight management in June 2025.
How it works in the body
A dual GLP-1 and glucagon receptor agonist. The GLP-1 activity reduces appetite and improves blood sugar control, while the glucagon activity increases energy expenditure by stimulating fat burning in the liver. This dual mechanism targets both sides of the energy balance equation simultaneously.
Research overview
Mazdutide's dual mechanism provides appetite suppression and insulin support through GLP-1 activation, plus enhanced fat burning and increased energy expenditure through glucagon activation. In the pivotal Phase 3 GLORY-1 trial (NEJM, 2025), the 6 mg dose achieved 14.0% body weight reduction at 48 weeks compared to 0.3% weight gain with placebo in Chinese adults. A high-dose Phase 1 trial reached 21.0% weight loss at 20 weeks. Meta-analyses across seven randomized trials (680 participants) confirm reductions in weight, waist circumference, blood pressure, and cholesterol. Side effects are primarily gastrointestinal (nausea, diarrhea, vomiting) and generally mild-to-moderate. Most clinical data comes from Chinese populations, so broader global trial results are still pending.
Who researches Mazdutide?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People researching cardiovascular health
Studied for effects on heart function, blood pressure, or vascular health.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
Important considerations for
Those with Personal/family history of MTC
AbsoluteDual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
Those with History of pancreatitis
HighGLP-1 class effect. Monitor for pancreatitis signs and symptoms.
Those with Severe gastroparesis
HighGLP-1 component slows gastric emptying significantly.
Those who are pregnant or breastfeeding
AbsoluteInvestigational compound. No reproductive safety data.
Safety & interactions
Do not use if
Personal/family history of MTC
AbsoluteDual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
History of pancreatitis
HighGLP-1 class effect. Monitor for pancreatitis signs and symptoms.
Severe gastroparesis
HighGLP-1 component slows gastric emptying significantly.
General cautions
Pregnancy
AbsoluteInvestigational compound. No reproductive safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(9)
Rated by level of concern
Gastrointestinal adverse events: diarrhea (28-41%), nausea (21-25%), vomiting (12-16%), decreased appetite (27-31%), abdominal distension (4-12%)
HighPMID 37943529 (Diabetes Care 2024); PMID 40421736 (NEJM 2025); PMID 41407859 (Nature 2026)
Heart rate increase: 5-17 bpm elevation above baseline observed across doses
ModeratePMID 36247927 (EClinicalMedicine 2022); PMID 40421736 (NEJM 2025)
Hypoglycemia risk: up to 16% at higher doses, especially when used with other antidiabetic agents; severe hypoglycemia rare
ModeratePMID 37943529 (Diabetes Care 2024); PMID 41407859 (Nature 2026)
Injection site reactions: 4-6% incidence
LowPMID 40421736 (NEJM 2025)
Immunogenicity: treatment-induced anti-mazdutide antibodies detected in 10-20% of participants, though no impact on efficacy or safety observed
LowPMID 41028652 (Drugs 2025); PMID 40421736 (NEJM 2025)
Potential thyroid C-cell effects: class concern for GLP-1 receptor agonists; no C-cell hyperplasia or thyroid tumors observed in trials but long-term surveillance needed
TheoreticalPMID 41028652 (Drugs 2025); GLP-1 receptor agonist class labeling (FDA)
Cardiovascular effects: supraventricular extrasystoles and sinus tachycardia observed in small percentages; all asymptomatic and transient
LowPMID 40421736 (NEJM 2025); PMID 36247927 (EClinicalMedicine 2022)
Limited long-term safety data: most evidence from trials of 20-48 weeks duration; post-marketing surveillance ongoing in China
ModeratePMID 41028652 (Drugs 2025, Mazdutide: First Approval); PMID 40421736 (NEJM 2025); PMID 41407859 (Nature 2026)
Weight regain upon discontinuation: as with other GLP-1 agonists, weight regain expected after stopping treatment
ModerateClass evidence: PMID 35441470 (Diabetes Obes Metab 2022, STEP-1 extension); PMID 38078870 (JAMA 2024, SURMOUNT-4)
Interaction summary(8)
Rated by direction with this peptide
Insulin (basal or prandial)
CautionHighAdding mazdutide to insulin raises hypoglycemia risk through additive glucose lowering; proactive insulin dose reduction and closer glucose monitoring are standard practice for GLP-1 receptor agonists and apply here. This is a class-level pharmacodynamic interaction rather than a mazdutide-specific drug-drug interaction study.
GLP-1 receptor agonist class labeling (FDA); PMID 37943529 (Diabetes Care 2024)
Sulfonylureas (glimepiride, gliclazide, glipizide) and glinides
CautionHighInsulin secretagogues combined with mazdutide increase hypoglycemia risk through additive glucose lowering, and secretagogue dose reduction at initiation is the usual mitigation. In the phase 2 T2D trial, hypoglycemia with mazdutide monotherapy was 10% vs 8% with placebo.
GLP-1 receptor agonist class labeling (FDA); PMID 37943529 (Diabetes Care 2024)
Orally administered drugs with narrow therapeutic index (levothyroxine, warfarin, digoxin, antiepileptics, immunosuppressants)
CautionModerateDelayed gastric emptying from GLP-1 receptor agonism can alter the rate and, less often, the extent of oral absorption, so narrow-index oral agents warrant monitoring (INR, TSH, drug levels) around initiation and dose escalation. No dedicated drug-drug interaction studies for mazdutide specifically have been published; this is extrapolated from class labeling.
GLP-1 receptor agonist class labeling (FDA, delayed gastric emptying)
General anesthesia and procedural sedation
CautionModerateRetained gastric contents despite standard fasting have been documented with GLP-1 receptor agonists, raising pulmonary aspiration risk; the ASA and the 2024 multisociety guidance advise individualized management of weekly agents before elective procedures and treating patients with persistent GI symptoms as full-stomach. Guidance is class-based, not mazdutide-specific.
American Society of Anesthesiologists guidance on GLP-1 receptor agonists (2023) and 2024 multisociety clinical practice guidance
Other GLP-1 receptor agonists, GLP-1/GIP co-agonists, and DPP-4 inhibitors
CautionModerateConcurrent use duplicates incretin pharmacology with no established added benefit and compounded gastrointestinal and heart-rate effects; combining a GLP-1 receptor agonist with another incretin agent is not recommended in class labeling and guidelines.
GLP-1 receptor agonist class labeling (FDA); PMID 41028652 (Drugs 2025)
SGLT2 inhibitors (empagliflozin, dapagliflozin)
SynergisticLowComplementary, non-overlapping mechanisms give additive HbA1c and weight benefit with low intrinsic hypoglycemia risk, and guidelines support the combination in type 2 diabetes. Shared volume-depletion potential means fluid status deserves attention during GI adverse events. No mazdutide-specific combination trial has been published; the synergy is class- and guideline-level.
ADA Standards of Care (combination therapy in type 2 diabetes)
Diuretics, ACE inhibitors and ARBs
CautionModerateMazdutide's high rate of diarrhea and vomiting can cause volume depletion, and superimposed diuretic or RAAS-blockade use raises the risk of acute kidney injury and symptomatic hypotension - a recognized class complication of GI adverse events rather than a direct pharmacologic interaction.
GLP-1 receptor agonist class labeling (FDA, acute kidney injury warning); PMID 37943529 (Diabetes Care 2024)
Alcohol
CautionTheoreticalAlcohol can worsen gastrointestinal intolerance and independently increases hypoglycemia risk in patients also taking insulin or sulfonylureas.
GLP-1 receptor agonist class labeling (FDA); general pharmacology of alcohol and insulin secretagogues
Known risks(9)
Gastrointestinal adverse events: diarrhea (28-41%), nausea (21-25%), vomiting (12-16%), decreased appetite (27-31%), abdominal distension (4-12%)
Heart rate increase: 5-17 bpm elevation above baseline observed across doses
Hypoglycemia risk: up to 16% at higher doses, especially when used with other antidiabetic agents; severe hypoglycemia rare
Injection site reactions: 4-6% incidence
Immunogenicity: treatment-induced anti-mazdutide antibodies detected in 10-20% of participants, though no impact on efficacy or safety observed
Potential thyroid C-cell effects: class concern for GLP-1 receptor agonists; no C-cell hyperplasia or thyroid tumors observed in trials but long-term surveillance needed
Cardiovascular effects: supraventricular extrasystoles and sinus tachycardia observed in small percentages; all asymptomatic and transient
Limited long-term safety data: most evidence from trials of 20-48 weeks duration; post-marketing surveillance ongoing in China
Weight regain upon discontinuation: as with other GLP-1 agonists, weight regain expected after stopping treatment
Drug interactions(6)
Insulin
Increased risk of hypoglycemia when used with insulin or insulin secretagogues. Insulin adjustment may be required. In Phase 2 trials, hypoglycemia incidence was up to 16% at higher doses.
Sulfonylureas
Enhanced hypoglycemic effect when co-administered. Monitor blood glucose closely and consider sulfonylurea dose reduction.
Metformin
Generally safe to combine; 66.4% of Phase 2 trial participants were on metformin background therapy. No significant interaction reported but additive GI side effects possible.
Oral contraceptives
GLP-1 receptor agonists delay gastric emptying, which may reduce absorption of oral medications. Consider monitoring efficacy of oral contraceptives.
Warfarin and oral anticoagulants
Delayed gastric emptying may affect absorption kinetics. INR monitoring is recommended when starting or adjusting mazdutide.
Other GLP-1 receptor agonists (semaglutide, tirzepatide)
Using mazdutide with other GLP-1 receptor agonists is not recommended: the overlapping mechanism adds risk of GI adverse events and hypoglycemia.
Research & benefits
Evidence base
- Evidence Level
- Strong
- Total Studies
- 10
Supported by multiple Phase 1b, Phase 2, and Phase 3 randomized controlled trials, two systematic reviews/meta-analyses, and regulatory approval in China. The GLORY-1 Phase 3 trial (NEJM, 2025) provided pivotal evidence for weight management. A Phase 2 trial in type 2 diabetes (Diabetes Care, 2023) demonstrated glycemic and weight benefits. Meta-analyses (Frontiers in Endocrinology, 2024; Diabetes Obesity & Metabolism, 2026) confirm consistent efficacy across trials. US Phase 2 results were published in August 2026.
Researched for(7)
Rated by confidence in the evidence
Significant Weight Loss
HighPhase 3 trial showed up to 14% body weight loss at 48 weeks versus placebo.
PMID 40421736 (N Engl J Med 2025;392:2215-2225); PMID 38092790 (Nat Commun 2023)
Glycemic Control
HighHuman RCTs show significant HbA1c reduction; approved in China for type 2 diabetes.
PMID 37943529 (Diabetes Care 2024); PMID 41407859 (Nature 2026, DREAMS-2); PMID 41028652 (Drugs 2025)
Dual Mechanism of Action
MediumGLP-1 effects proven in humans; added energy-expenditure benefit is mechanism-based, not directly measured.
PMID 41028652 (Drugs 2025, Mazdutide: First Approval); PMID 36247927 (EClinicalMedicine 2022)
Cardiovascular Risk Factor Improvement
HighPhase 3 trial showed improved cardiometabolic risk factors; no outcome trial yet for heart events.
PMID 40421736 (N Engl J Med 2025)
Waist Circumference Reduction
HighConfirmed in multiple human trials, including phase 3 evidence versus placebo.
PMID 40421736 (N Engl J Med 2025); PMID 36247927 (EClinicalMedicine 2022)
Convenient Dosing
MediumOnce-weekly dosing is confirmed in trials; convenience itself has not been separately tested.
PMID 40421736 (N Engl J Med 2025); PMID 41407859 (Nature 2026)
Liver Enzyme Improvement
MediumA randomized human trial found reduced ALT at 24 weeks; clinical liver outcomes remain unproven.
PMID 38092790; Nature Communications 2023; https://www.nature.com/articles/s41467-023-44067-4
Benefits(7)
Significant Weight Loss
Glycemic Control
Dual Mechanism of Action
Cardiovascular Risk Factor Improvement
Waist Circumference Reduction
Convenient Dosing
Liver Enzyme Improvement
Key studies(5)
Ji L, Jiang H, Bi Y, et al.
New England Journal of Medicine
2025
Phase 3 RCT: At 48 weeks, mazdutide 4 mg and 6 mg achieved -11.0% and -14.0% body weight reduction vs +0.3% placebo in 610 Chinese adults with obesity/overweight.
Zhang B, Cheng Z, Chen J, et al.
Diabetes Care
2023
Phase 2 RCT (n=248): HbA1c reductions of -1.41% to -1.67% and dose-dependent weight loss up to -7.1% over 20 weeks. GI adverse events were mild-moderate and transient.
Nalisa DL, Jiang H, et al.
Frontiers in Endocrinology
2024
Meta-analysis of 7 RCTs (680 participants): Mean weight reduction -6.22% overall, -8.44% in non-diabetic participants. Significant reductions in blood pressure, cholesterol, and triglycerides.
Azam MH, et al.
Diabetes, Obesity and Metabolism
2026
Meta-analysis of 5 RCTs in non-diabetic obese adults: Mean body weight reduction -12.42%, absolute weight loss -9.76 kg, waist circumference decrease -7.98 cm.
Shirley M
Drugs
2025
Review of mazdutide's first regulatory approval in China (NMPA) for chronic weight management (June 2025) and type 2 diabetes (September 2025) as the world's first dual GLP-1/glucagon receptor agonist.
What research suggests over time
Weeks 2-4
Phase 2 RCTAppetite reduction and early weight loss begin as dose titrates; GLP-1/glucagon dual mechanism active.
Months 2-3
Phase 2 (Diabetes Care 2023)~7% weight loss at 20 weeks at therapeutic doses; HbA1c reductions of 1.41-1.67% in T2DM.
Long-term
Phase 3 (GLORY-1 NEJM 2025)Mean -11.0% to -14.0% body weight at 48 weeks across the GLORY-1 Phase 3 dose arms vs +0.3% placebo. Approved in China; US Phase 2 completed.
Regulation & availability
Why researchers look at it
Became the world's first approved dual GLP-1/glucagon agonist (China, June 2025), with a high-dose Phase 1 trial reaching 21% weight loss at just 20 weeks — potentially surpassing GLP-1-only drugs by adding glucagon-driven fat burning. Lilly's US Phase 2 trial is completed; US Phase 3 timing remains unconfirmed.
- Estimated cost
- No US-approved product; US Phase 2 completed.
- FDA status
- Mazdutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. US Phase 2 results were published in August 2026. US Phase 3 and approval dates remain unconfirmed. China-approved for obesity (June 2025) and type 2 diabetes (September 2025).
- WADA status
- GLP-1 receptor agonists are not currently on the WADA Prohibited List. However, athletes should verify current status as WADA reviews substances annually. Mazdutide's weight loss effects could potentially attract scrutiny in weight-class sports.
- Prescribability
- Mazdutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. Approved in China as Xinermei for obesity (June 2025) and type 2 diabetes (September 2025).
- Availability
- Approved and commercially available in China as Xinermei (marketed by Innovent Biologics). Not yet available in the United States or Europe. Lilly's US Phase 2 obesity study, NCT06124807, conducted under master protocol NCT06143956, is completed. In the US it may be accessible through clinical trial enrollment.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
Approved in China (NMPA) for obesity (June 2025) and T2D (Sept 2025)
Regulatory timeline(11)
- 2020IND ApprovalInnovent Biologics received IND approval to begin clinical trials of mazdutide (IBI362) in China.
- 2021-2022Phase 1b TrialsMultiple Phase 1b dose-escalation trials conducted in China, UK, and Germany testing doses from 0.05 mg to 10 mg.
- 2022-2023Phase 2 TrialsPhase 2 trials in obesity (Nature Communications, 2023) and type 2 diabetes (Diabetes Care, 2023) demonstrated significant efficacy.
- 2023-2024Phase 3 GLORY-1 TrialPivotal Phase 3 trial in Chinese adults with obesity published in NEJM (2025), showing -11% to -14% weight loss at 48 weeks.
- February 2024NMPA Application Accepted (Obesity)China's NMPA accepted the application for chronic weight management indication.
- August 2024NMPA Application Accepted (T2D)China's NMPA accepted the application for type 2 diabetes indication.
- June 2025NMPA Approval (Obesity)Mazdutide (Xinermei) approved in China for long-term weight management in adults with BMI >= 28 or BMI >= 24 with comorbidities. First dual GLP-1/glucagon agonist approved worldwide for obesity.
- September 2025NMPA Approval (T2D)Mazdutide (Xinermei) approved in China for glycemic control in adults with type 2 diabetes.
- 2025-2026US Phase 2 Trials (Eli Lilly)Lilly's US Phase 2 obesity study, NCT06124807, conducted under master protocol NCT06143956, is completed. Lilly holds rights to mazdutide outside of China.
- 2026-2027 (projected)US Phase 3 TrialsPhase 3 trials in the US expected to begin pending Phase 2 results.
- 2028-2029 (projected)Potential US FDA ApprovalNDA submission estimated 2027-2028 with FDA approval potentially in 2028-2029. Priority review could accelerate timeline to late 2027.
Sources & FAQs
Research sources(9)
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (NEJM 2025)
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes (Diabetes Care 2023)
- Mazdutide systematic review and meta-analysis (Frontiers in Endocrinology 2024)
- Mazdutide meta-analysis in non-diabetic adults (Diabetes Obes Metab 2026)
- Mazdutide: First Approval (Drugs 2025)
- Phase 2 RCT in Chinese overweight/obesity (Nature Communications 2023)
- Phase 1b MAD trial 9 mg and 10 mg (EClinicalMedicine 2022)
- ClinicalTrials.gov: Mazdutide Phase 2 T2D trial
- NMPA Approval Announcement (PR Newswire 2025)
Frequently asked questions(4)
How does mazdutide differ from semaglutide (Wegovy/Ozempic)?
Mazdutide is a dual agonist targeting both GLP-1 and glucagon receptors, while semaglutide targets only GLP-1 receptors. The added glucagon receptor activation promotes increased hepatic fat oxidation and energy expenditure, potentially offering superior weight loss and metabolic benefits. Phase 3 data showed -14% weight loss at 48 weeks with the highest mazdutide dose.
What are the most common side effects of mazdutide?
The most common side effects are gastrointestinal: diarrhea (up to 41%), decreased appetite (up to 31%), nausea (up to 25%), and vomiting (up to 16%). These are generally mild to moderate, occur more frequently during dose escalation, and decline over time. Heart rate increases of 5-17 bpm have also been observed.
Is mazdutide available in the United States?
No. Mazdutide is currently only approved in China (as Xinermei). Lilly's US Phase 2 trial is completed. A US approval date is unconfirmed. Patients may access it through clinical trial enrollment.
Can mazdutide be used for conditions other than obesity and diabetes?
Mazdutide is currently being investigated for metabolic dysfunction-associated fatty liver disease (MAFLD), obstructive sleep apnea, and alcohol use disorder. A study also explored its potential to mitigate diabetes-associated cognitive dysfunction. These indications are still in early clinical evaluation.